ERBB2 and breast cancer: It has been reported that 30% of luminal B breast cancer tumors convert to different subtypes in metastatic foci, and 14.3% of luminal A and B breast cancer tumors convert to HER2-enriched tumors (Cejalvo et al., 2017).